Orchid Pharma (ORCHPHARMA)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 69.84% aligns ownership with minority shareholders.
• Book value of ₹261.46 provides some tangible asset backing, although price is 2.17 times book.
• Latest quarter sales of ₹207 Cr show the business still has meaningful scale.
• The stock is closer to its 52-week low of ₹480 than its high of ₹1,133, so some optimism has already been removed from the price.

Concerns

• Latest quarter net loss of ₹13 Cr on sales of ₹207 Cr; the business is losing money at the bottom line.
• ROE of 3.34% and ROCE of 8.07% indicate poor returns on capital employed.
• Sales growth of -4.63% and profit growth of -126.47% show fundamental deterioration.
• P/E of 120.99, zero dividend yield and a Piotroski F-score of 3/9 leave no margin of safety.

AI Analysis

Let me look at Orchid Pharma the way Graham would: price is what you pay, value is what you get. At ₹566.80, the market values it at ₹3,143 Cr—that is 120.99 times trailing earnings, yet the latest quarter produced a net loss of ₹13 Cr on sales of ₹207 Cr. That is not a sign of business quality. Return on equity is just 3.34%, return on capital employed is only 8.07%, sales are shrinking 4.63%, and profit growth has collapsed 126.47%. These are not the numbers of a company with a durable moat. The Piotroski F-score of 3/9 reinforces my concern about financial health. Book value is ₹261.46, but I am asked to pay 2.17 times book; the asset cushion is not enough, and I am paying a large premium to net assets. There is no dividend yield, so I receive nothing while I wait. Graham would demand either cheapness or growth; I see neither. Promoter holding of 69.84% is a positive for alignment, but even that cannot turn a weak business into an attractive investment. The 52-week range of ₹480 to ₹1,133 shows how much this stock has swung; being near the lower end does not automatically create a margin of safety. This may eventually be a turnaround, but I do not buy possibilities; I buy demonstrated earning power. I would need to see rising sales, positive profits, and higher returns on capital. Today, the FairStock Score of 0/100 and my own discipline both say: avoid.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer